LOGOLOGOLOGOLOGO
    • About us
      • What we do
      • Who we are
        • Governance
        • Staff
        • Vacancies
    • Members
      • EuropaBio Members
      • About Membership
    • How we work
      • Healthcare Biotechnology Council
        • Patient BioForum
        • Study – Impact of the EU’s General Pharmaceutical Legislation
      • Industrial Biotechnology Council
        • EFIB
        • Microorganisms
      • National Associations Council
      • SME Platform
      • Biomanufacturing Platform
        • Biotechnology in our Lives
    • Activities
      • 25 Years of Innovation
      • The EU Biotech Act
      • European Biotech Week
      • EU Projects
        • PRIMED Project
        • APROVALS Project
    • News & Events
      • News
      • Events
    • Library
    Become a member
    ✕

    Safety aspects of microorganisms deliberately released into the environment

    19/07/2024
    LITERATURE REVIEW

    Safety aspects of microorganisms deliberately released into the environment

    (Alexandra Lensch, Hanna Abbas Lindfors, Elke Duwenig, Tobias Fleischmann, Carsten Hjort, Sirpa O. K¨arenlampi, Lucie McMurtry, Emily-Denise Melton, Mikael Rørdam Andersen, Ryan Skinner, Markus Wyss, Richard van Kranenburg)

    ABSTRACT

    Microorganisms are used in a variety of sectors, including food and feed production, agricultural or environmental applications, and can be optimized for efficacy, safety and sustainability using modern biotechnology techniques. In the EU, genetically modified microorganisms (GMMs) are typically used as production organisms for food and feed products, including enzymes, amino acids, vitamins, flavourings, and oligosaccharides under the Contained Use Directive. Applications involving live GMMs would fall under the Deliberate Release Directive. However, its relevant regulations and guidelines are so far not supporting the access to market of GMMs. In this literature review, we examine what is already known or can be inferred about the safety of microorganisms deliberately released into the environment across sectors. We conclude that there is sufficient evidence supporting the establishment of a European framework for the risk assessment of GMMs deliberately released into the environment, which would enable timely market access for live GMM products.

    Read the full article below.

    Safety aspects of microorganisms deliberately released into theenvironmentDownload
    Share
    Communications Team
    Communications Team

    Related posts

    13/02/2026

    The Association of Biopharmaceutical Manufacturers in Latvia (BRAL) joins EuropaBio: Promoting Access to Innovative Therapies


    Read more
    11/02/2026

    Call for tender: EU Biotech and Life Sciences Alliance MEP Group Secretariat services 2026


    Read more
    06/02/2026

    OECD: A comparison of the innovation and regulatory environments for biotechnology and biosolutions across the European Union and the United States


    Read more

    Important links

    • The Association of Biopharmaceutical Manufacturers in Latvia (BRAL) joins EuropaBio: Promoting Access to Innovative Therapies
    • Call for tender: EU Biotech and Life Sciences Alliance MEP Group Secretariat services 2026

    Categories in our Newsroom

    EBIO-white

    EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

    Contact us

    Extra links

    Members
    Staff
    Privacy policy
    Legal & cookies
    Events
    Newsroom

    Become a member

    Media pack

    © 2026 Europabio. All Rights Reserved. Designed by EYAS
    Become a member

    Vitamin B2

    The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

    Insulin

    Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.

    Detergents

    Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

    Clothes

    Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

    Algal Omega 3

    Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

    Cheese

    Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.